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Background: Adjuvant post-mastectomy radiotherapy (RT), which is often unpredicted, is known to
increase complications following immediate breast reconstruction (IBR).
Aim: To investigate the role of sentinel lymph node biopsy (SLN) in predicting RT and improving the
choice of IBR.
Patients and methods: All patients who had mastectomy and IBR between January 2004 and January 2007
were reviewed retrospectively. Axillary staging (clearance or SLN) was performed at the same time until
October 2005 (Group 1), when the Unit’s protocol was updated to perform SLN initially prior to
mastectomy and IBR (Group 2). Patients in Group 2 with positive SLN were offered either a delayed
reconstruction or a temporary subpectoral immediate tissue expander, while all options were offered if
SLN was negative and in Group 1 patients.
Results: One hundred and thirty-nine patients were reviewed. 20 patients received unexpected RT in
Group 1 (14 tissue expander, 4 Latissimus Dorsi ﬂap with an implant and 2 DIEP ﬂaps) compared to 11
patients in Group 2 who had a temporary tissue expander due to expected RT (P¼ 0.03). Unexpected RT
caused delayed complications in 14 patients (70%) compared to no delayed complications in patients
who received expected RT in Group 2.
Conclusion: SLN biopsy before IBR helps to predict RT and avoids its complications on breast recon-
struction. Patients with positive SLN biopsy are best offered a temporary subpectoral tissue expander for
IBR.
 2012 Surgical Associates Ltd. Published by Elsevier Ltd. All rights reserved.1. Background
Skin sparing mastectomy and immediate breast reconstruction
has been shown to be oncologically safe,1,2 psychologically bene-
ﬁcial3,4 and cost effective5 in comparison with delayed breast
reconstruction. Different factors have been described to inﬂuence
the choice of the technique of immediate breast reconstruction.
These include: patient ﬁtness, breast size, body habitus, contra-
lateral breast, stage of the disease, personal preference and post-
mastectomy radiotherapy.6,7
Post-mastectomy adjuvant radiotherapy causes adverse effects
on both autogenous and implant based reconstructions.6 It is
indicated in high-risk breast cancer patients, including positive
axillary lymph nodes and involved resection margins.8 It reducesurdeep.mannu@nnuh.nhs.uk
ciates Ltd. Published by Elsevier Ltloco-regional recurrence and increases the overall survival in this
group of patients.9 The inability to accurately determine which
patients will require post-mastectomy radiotherapy has increased
the complexity of planning for immediate breast reconstruction.
Lymphatic mapping with sentinel lymph node biopsy has
decreased the need for complete axillary lymph node dissection in
women with clinically node-negative breast cancer.10e13 In clini-
cally node-negative patients who choose mastectomy and imme-
diate breast reconstruction, the sentinel lymph node status on ﬁnal
histologymay complicate the treatment if ametastasis is found that
was not recognized on intraoperative assessment.14 The subse-
quent completion axillary dissection can compromise the vascular
pedicle to the Latissimus Dorsi ﬂap, or the thoracodorsal pedicle,
which is often used as a recipient vessel for free ﬂaps.15 If patients
require post-mastectomy adjuvant radiotherapy, it can adversely
affect the outcome of an implant based or autogenous recon-
structed breast.6
However, themajor problem of performing sentinel lymph node
biopsy at the same time of mastectomy and immediate breastd. All rights reserved.
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assessment. A published European survey of current practicewithin
145 units processing intraoperative sentinel lymph node assess-
ment showed that 101 units (70%) used frozen section , 28 units
(19%) use both frozen section and imprint touch cytology while 16
units (11%) use touch imprint cytology alone.16 The reported sensi-
tivity of frozen section ranges from 57% to 74% with a very high
reported speciﬁcity.17 It is expensive, operator dependant, requiring
a skilled biomedical scientist and dedicated histopathologist for
each surgical session. Frozen section is inferior to parafﬁn sections
and may miss subtle lymph node metastases particularly in lobular
cancer.17 Furthermore it results in irreversible tissue losswhichmay
underestimate the sentinel lymph node.17 Touch imprint cytology
although requires signiﬁcant expertise to interpret cytological
material, the preparation time and cost of cytological specimens is
less than for frozen section. In addition there is no loss of tissue.15 In
a recent meta-analysis, the pooled estimate of the sensitivity of
touch implant cytology was 63% and speciﬁcity 99%.18 The false
negative results in touch imprint cytology are more common in
micrometastatic disease and in lobular carcinoma.17 Intraoperative
molecular techniques have emerged in the ﬁeld of detecting lymph
node involvement but require homogenization of the lymph node
tissue, which means that direct comparison with histological tech-
niques is impossible. They also have various practical operative
restraints limiting their use.
Our unit operates on 600 breast cancer patients per year,
including 200 from the breast cancer screening program. The
objective of this study is to evaluate the impact of sentinel lymph
node biopsy, as an initial procedure, before mastectomy and
immediate breast reconstruction in predicting post-mastectomy
radiotherapy and hence improving the choice of the reconstruction.
2. Patients and methods
A retrospective observational review of all patients who had mastectomy and
immediate breast reconstruction between January 2004 and January 2006 at the
Breast Surgery Unit, Norfolk & Norwich University Hospital. Surgery was performed
either by an oncoplastic surgeon or as a conjoint procedure of breast and plastic
surgeons.
2.1. Information recorded
Information collected included: patient age, operating surgeon, type of lymph
node evaluation (axillary node clearance or sentinel lymph node biopsy), type of
immediate breast reconstruction (tissue expander, Latissimus Dorsi ﬂap or free
ﬂaps), date of surgery, pathological details of the cancer and adjuvant treatment.
2.2. Axillary staging protocol
Patients with clinically node-negative breast cancer had an ultrasound scan of
the axilla as part of their initial staging, and biopsy was performed for suspicious
nodes. Patients with proven positive nodes had axillary clearance directly without
the need for sentinel lymph node biopsy. The axillary staging protocol was updated
at Norfolk & Norwich University Hospital in October 2005. Patients were classiﬁed
into two groups accordingly.
Group 1: 67 patients who had their axillary staging (axillary node clearance or
sentinel node biopsy) performed at the same time of mastectomy and imme-
diate reconstruction until October 2005.
Group 2: 72 patients who had initial sentinel node biopsy performed separately
prior tomastectomy and immediate reconstruction in the updated protocol after
October 2005.
Patients in Group 1 were offered all options of immediate breast reconstruction.
Tissue expander breast reconstruction (T/E) was performed either as a single
(McGhan Style 150 double lumen implant with mini remote port) or two stage
procedure (McGhan Style 133 temporary tissue expander, to be replaced byMcGhan
Style 410/510 permanent implant). This choice was achieved based on the surgeon’s
and the patient’s preference. The 72 patients in Group 2 with positive sentinel nodes
were offered delayed reconstruction or mastectomy, axillary clearance and imme-
diate reconstruction with a temporary subpectoral tissue expander (McGhan Style
133), to be replaced by an autogenous reconstruction after completion of cancertreatment (chemotherapy and radiotherapy). This protocol allowed patients to
beneﬁt from all advantages of immediate breast reconstruction such as maximum
skin preservation, minimal scarring as well as better psychological outcome. It also
works to avoid the possible complications and effects of radiotherapy on the
permanent reconstruction. All immediate breast reconstruction options were
offered to patients in Group 2, if the sentinel lymph node biopsy was negative
(Algorithm 1).
2.3. Adjuvant treatment
The decision regarding further adjuvant treatment was made after discussion in
multidisciplinary teammeeting. Indications for post-mastectomy radiotherapywere
positive axillary lymph nodes or positive excision margins. Chemotherapy was
offered to high-risk patients according to the National Guidelines. Hormonal
manipulation was offered to patients with hormone receptor positive carcinoma.
2.4. Statistical analysis
Statistical analysis was performed using Statistical Package for Social Sciences
(SPSS) version 17 software. The two groups were compared. Associations between
variables in both groups were assessed using chi-squared and t-test.3. Results
Types of immediate reconstructions: 139 immediate breast
reconstructions were performed for 139 patients in our unit over
the deﬁned time period. There was a signiﬁcant increase in the
number of immediate breast reconstructions performed over the 3
years period of the study (34 in 2004, 43 in 2005 and 62 recon-
structions in 2006).
The patients’ mean age was 50 (range 37e65) years. There was
no signiﬁcant difference in patients’ age in the two groups (p¼ 0.1).
The mean age for patients who had free ﬂap reconstruction was
53.1 years, those who had tissue expander was 53 years and
patients who had Latissimus Dorsi ﬂap reconstruction was 56.7
years (p¼ 0.58).
The most common type of immediate breast reconstruction in
Group 1 was tissue expander (n¼ 33) followed by free ﬂap
reconstruction (n¼ 17) and Latissmus Dorsi ﬂap (n¼ 17). In Group
2 the most common type of reconstruction was tissue expander
(n¼ 35) followed by free ﬂap reconstruction (n¼ 27) and Lat-
issmus Dorsi ﬂap (n¼ 10) (Table 1). The increase of free ﬂap
reconstructions in Group 2 patients was statistically signiﬁcant
(p 0.0001).
Seventy-eight immediate reconstructions were performed for
invasive carcinoma, and 61 for ductal carcinoma in-situ (DCIS). The
type of immediate reconstruction performed was signiﬁcantly
related to the pathology (p¼ 0.01). The most common recon-
struction performed for invasive carcinoma was tissue expanders
(n¼ 46) followed by free ﬂap reconstruction (n¼ 17), and Lat-
issimus Dorsi ﬂap (n¼ 15). For non-invasive pathology 27 recon-
structions performed using free ﬂaps, 22 using tissue expander and
12 reconstructions using Latissimus Dorsi ﬂap.
Thirty-four patients had positive lymph nodes and 105 recon-
structions were performed for negative axilla. Tissue expander was
the most common type of reconstruction (n¼ 23) performed for
patients who had positive lymph node followed by free ﬂap
reconstruction (n¼ 6), and Latissimus Dorsi ﬂaps (n¼ 5). Recon-
structions performed for negative axilla were tissue expander
(n¼ 45), free ﬂaps (n¼ 38) and Latissimus Dorsi ﬂaps (n¼ 22),
(p¼ 0.03).3.1. Axillary staging
Compared to Group 1, the number of axillary node clearance
was signiﬁcantly reduced, while the sentinel lymph node biopsy
was signiﬁcantly increased in Group 2 (p< 0.0001) (Table 1).
Table 2






Adjuvant radiotherapy 20 11 31 0.031
Patients who had no radiotherapy
Tissue expander (one stage) 7 4 11
Node-negative (Clinical and ultrasound) breast cancer
Patients considered for mastectomy and IBR
SLN biopsy prior to the mastectomy and IBR
Positive SLN                                           Negative SLN
Temporary Sub-pectoral
Tissue Expander
Tissue Expander        LD flap          LD with implant              Free flaps 
(one or two stages)                                                                     
Completion of cancer 
treatment
Autogenous reconstruction
Algorithm 1. Clinical decision making for immediate breast reconstruction in node negative breast cancer patients. SLN, sentinel lymph node biopsy; IBR, immediate breast
reconstruction; LD, Latissimus Dorsi.
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In Group 1, 20 patients required unexpected post-mastectomy
radiotherapy due to positive axillary nodes, which was only
discovered after the ﬁnal histologywas available. In Group 2, eleven
patients required post-mastectomy radiotherapy, which was
expected in all patients (p< 0.0001). The types of reconstruction
performed in patients who required post-mastectomy radiotherapy
are shown in Table 2. In Group 1, 14 patients who required unex-
pected post-mastectomy radiotherapy received tissue expander
reconstruction (10one stage, and4 twostages procedure), 4 patients
had latissmus dorsi ﬂap with a ﬁxed volume implant and 2 patients
had free (DIEP) ﬂap. In Group 2,11 patientswere expected to require
post-mastectomy radiotherapy, due to positive sentinel lymphnode
biopsy, and all received a temporary subpectoral tissue expander.Table 1






Mean age (years) 50.8 51.2 50 0.1
Axillary staging





Tissue expander 33 35 68 <0.0001
LD implant 17 10 27
Free ﬂaps 17 27 44
IBR, immediate breast reconstruction; LD, Latissimus Dorsi.3.3. Complications
Table 3 shows the delayed complications in patients who
received unexpected radiotherapy in Group 1 (20 patients) as
a consequence of radiotherapy. Fourteen patients (70%) developed
complications that required further surgery. Three patients lost theTissue expander (2 stages) 12 20 32
LD with implant 12 6 18
LD autogenous 1 4 5
DIEP ﬂap 9 22 31
Other free ﬂaps 6 5 11
Complications e e e
Patients who had radiotherapy
Tissue expander (one stage) 10
Tissue expander (2 stages) 4 11
LD with implant 4
LD autogenous e
DIEP ﬂap 2
Other Free ﬂaps e
Complications 14 e
IBR, immediate breast reconstruction; LD: Latissimus Dorsi; DIEP, deep inferior
epigastric perforator.
Table 3

















LD with implant 1 1
LD autogenous
DIEP ﬂap 2
LD, Latissimus Dorsi; DIEP, deep inferior epigastric perforator.
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patients) or severe capsular contracture and associated pain (1
patient). Patients in Group 2 who received expected radiotherapy
(11 patients) had further autogenous reconstruction without any
complications.
4. Discussion
This is an observational retrospective study which compares the
immediate reconstruction outcome in light of adopting the sentinel
node biopsy approach as the procedure of choice in axillary staging
of clinically node negative breast cancer patients19e21 at the Nor-
folk & Norwich University Hospital.
4.1. Indications of post-mastectomy RT
Positive lymph nodes remain the main indication for the post-
mastectomy radiotherapy.22 Therefore determining the status of
the axillary lymph nodes pre-operatively can signiﬁcantly affect the
choice of immediate breast reconstruction.23 The use of pre-
mastectomy sentinel lymph node biopsy may provide guidance
on whether a patient will require post-mastectomy radiotherapy
provided that the margins of resection are clear. The number of
positive lymph nodes required to justify radiotherapy has been
widely debated. There is substantial evidence to support post-
mastectomy radiotherapy for patients who have four or more
involved lymph nodes.22,24e26 However, patients with one to three
positive lymph nodes are at high loco-regional recurrence risk after
mastectomy.27e31 The beneﬁts of radiotherapy for those patients
has been documented in some studies.32e35 The absolute risk
reduction in local recurrence rate in patients with one to three
positive lymph nodes is currently the focus of the selective use of
postoperative radiotherapy after mastectomy (SUPREMO) trial.
SLN may be the only positive lymph node in the axilla in up to
85% of patients. Furthermore, patients with 1e3 positive nodesmay
be recruited into the SUPREMO trial with 50% chance of receiving
post-mastectomy radiotherapy. However, the SUPREMO trial was
not available during our study period and all patients with positive
lymph glands were considered for post-mastectomy radiotherapy
during the study.
Positive resection margin following mastectomy is also an
indication for post-mastectomy radiotherapy. In our study, none of
the patients had radiation therapy due to positive resection
margins.
4.2. Positive sentinel lymph node
Having a positive sentinel node traditionally suggested axillary
node clearance. The Z0011 trial was a randomized trial of axillary
node dissection vs no further surgery in women with clinical T1e2N0 M0 breast cancer who had a positive sentinel node. The
conclusion drawn from the results was that no clinical beneﬁt of
axillary lymph node clearance was apparent for patients with
limited nodal disease.36 However there are a number of criticisms
regarding this trial. There are several studies looking at the
signiﬁcance of the low volume metastases (ITC, micro- and mac-
rometastases) within the SLN. The majority of patients in the
Z0011 trial had a low tumour burden with 41% micrometastases or
ITCs. There was no detailed standardization of the radiation ﬁelds.
It is possible that the SLN only group obtained indirect radio-
therapy by virtue of a large area of the axilla being within the
radiation ﬁeld. There was no speciﬁc analysis of adjuvant systemic
therapy used. The study failed to achieve its target accrual and
there is need for longer follow up. There was a lack of power to
determine the survival beneﬁt.36 Our current practice is a selective
policy to consider axillary node clearance in patients who have
low volume metastasis in sentinel lymph nodes. In high-risk
tumours (grade 3, presence of lymphvascular invasion, T2
hormone receptor negative or Her2 positive) axillary clearance is
considered. In low risk tumours adjuvant treatment only is
considered.
4.3. Intraoperative assessment of sentinel lymph node
If the SLN is positive, it is better to avoid deﬁnitive autoge-
nous or implant based IBR and only consider temporary sub-
pectoral tissue expander reconstruction. The accuracy of
intraoperative assessment of the SLN remains debatable. Great
interest has developed into the use of molecular techniques
examining mRNA from genetic markers overexpressed in cancer
cells in homogenized sentinel node tissue. The technique
utilizes reverse transciptase-polymerase chain reaction (RT-PCR)
or one step nucleic acid ampliﬁcation (OSNA).37 The genetic
markers most commonly utilized include mammaglobin 1 (MGB
1) and cytokeratin 19 (CK 19). The reported sensitivity was 91%
and speciﬁcity was 97% using this technique.38 Nonetheless
there are several disadvantages which have restricted molecular
techniques from entering widespread mainstream use. The fact
that these techniques require homogenization of the lymph
node tissue means that direct comparison with histological
techniques is impossible. This can lead to an increased false
positive rate.17
In our opinion intraoperative techniques in evaluating sentinel
node biopsy are not a complete solution when determining
whether or not to proceed with deﬁnitive immediate breast
reconstruction due to many difﬁculties. Firstly, it will be difﬁcult to
morally obtain informed consent for two completely different
procedures with differing potential complications depending on
the intraoperative results of the SLN. From the patient’s point of
view undergoing such an operation, one could come out with
a radical contrast in appearances. Psychologically it is very trau-
matic for a patient to have such a level of uncertainty around an
upcoming operation. Secondly it would be difﬁcult to estimate the
amount of theatre time required as the operation will depend on
the intraoperative evaluation of SLN. The decision to proceed with
ﬂap immediate reconstruction will add a substantial time onto the
procedure compared to a temporary subpectoral tissue expander.
The difference in the theatre time, cost, expertise and resources
required for these different procedures is immense; hence it would
be impossible to organize upcoming theatre lists effectively with
such variables. In our opinion, deﬁnition of axillary staging remains
important information needed before considering mastectomy
and immediate breast reconstruction even in the presence of
new techniques to determine sentinel lymph node status
intraoperatively.
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Although there is a considerable variation of the results of
different series, all reports agree with high complication rates if
radiotherapy is given after implant based reconstruction.6 In one
study, 32% of the irradiated group had symptomatic capsular
contractures, whereas none occurred in the control group.39
Capsular contracture can distort the appearance of the recon-
structed breast and cause chronic chest wall pain and tightness.40
Radiation therapy can also lead to painful expansion, increase
rates of infection and implant extrusion.6 The complication rates
were reported to be as high as 70%41,42 in implant reconstruction
alone, or up to 40% if the implant was covered by a myocutaneous
ﬂap.43 In our study, nearly half of the patients were served with
tissue expander reconstruction in both groups.We found thatmany
of our patients still request this type of reconstruction as it does not
require extra scars and still achieves a satisfactory result to meet
those patients’ expectations. Some of our patients request one stage
tissue expander reconstruction as it avoids, in theory, further
surgery. Table 3 shows complications in patients who received
unexpected radiotherapy in Group 1 (overall complication rate is
70%). Ten patients in Group 1 had one stage double lumen tissue
expander-implant reconstruction followed by unexpected radio-
therapy (Table 2), 2 patients had their implants removed due to
delayed infection and implant extrusion and 4 patient had capsular
contracture, which required further surgery. In Group 2 patients,
we only offered this form of reconstruction for lymph node nega-
tive patients and none of these 4 patients needed radiotherapy or
any further surgery (Table 2).
In Group 1, four patients had post-mastectomy radiotherapy
after reconstruction with Latissimus Dorsi ﬂap and ﬁxed volume
implant reconstruction and two patients developed capsular
contracture, which required further surgery (implant removed due
to pain in one patient and capsulotomy and implant replacement in
the other patient).
An autologous breast reconstruction can be adversely affected
by post-mastectomy radiotherapy, which can result in contracture
of the breast skin and atrophy of the ﬂap. It can also result in a ﬁrm
breast that is asymmetric with the contra-lateral breast. This
anatomical distortion of the reconstructed breast can progress over
time, which can be especially noticeable in patients with small
breasts.40 The body of evidence in the literature has shown that
radiotherapy increases the rate of complications of TRAM (trans-
verse rectus abdominis myocutaneous ﬂap) reconstruction.44 In
2002, Rogers and Allen45 reported that patients who received
postoperative radiotherapy had higher incidences of fat necrosis,
ﬁbrosis, shrinkage, and contracture of the DIEP ﬂap than patients
who did not receive radiotherapy. In our study 2 patients were
served by DIEP ﬂap and required unexpected radiotherapy in Group
1 and both patients developed delayed marked ﬂap atrophy and
ﬁrmness with obvious asymmetry. In contrast patients in Group 2
whowere served by free ﬂaps had no radiotherapy and no reported
delayed complications.
4.5. Dose distribution of RT
It was initially thought that the dose distribution of post-
mastectomy radiotherapy is negatively affected by the presence
of a tissue expander. In these cases a delayed autogenous recon-
structionwas preferred. However the majority of studies now show
that immediate tissue expander/implant reconstruction is an
acceptable surgical option when followed by postoperative radio-
therapy.46e49 Concerns regarding reduced dosimetry in patients
undergoing immediate expander-implant reconstruction are
unfounded as post-mastectomy radiotherapy can achieve excellentlocal control.50 In clinical practice small dose perturbations at the
interface between the implant and surrounding tissue nullify each
other.51e53
In conclusion, sentinel lymph node biopsy as a separate proce-
dure before mastectomy and immediate reconstruction can help in
predicting post-mastectomy radiotherapy. It improves the choice of
the suitable form of reconstruction. Patients who receive unex-
pected radiotherapy after immediate breast reconstruction have
a high risk of delayed complications. Sentinel lymph node biopsy
before mastectomy and immediate breast reconstruction plays
a signiﬁcant role in avoiding the complications thatmay result from
inappropriate choice of reconstruction.
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